CD4 and neoplasm: This low frequency, compared with telomerase-specific CD4+ Th1 response, could be related to the use of highly selected and promiscuous HLA class II-binding peptides that cover more than 85% of the population,22,24 or to the preferential localisation of these effector cells in the tumour.